Table 1.
Characteristics of the Childhood Cancer Survivor Study cohort*
| Characteristic | Overall cohort (n = 14 359) | Survivors without a subsequent neoplasm (n = 12 957) | Survivors with a subsequent neoplasm (n = 1402) | P |
| Mean age at diagnosis of primary cancer, y (SD) | 7.8 (5.8) | 7.5 (5.5) | 10.5 (6.1) | <.001 |
| Sex, No. (%) | <.001 | |||
| Male | 7714 (53.7) | 7119 (54.9) | 595 (42.4) | |
| Female | 6645 (46.3) | 5838 (45.1) | 807 (57.6) | |
| Race, No. (%) | <.001 | |||
| White, non-Hispanic | 11 943 (83.2) | 10 699 (82.6) | 1244 (88.7) | |
| Black, non-Hispanic | 668 (4.7) | 641 (4.9) | 27 (1.9) | |
| Hispanic | 751 (5.2) | 708 (5.5) | 43 (3.1) | |
| Other | 946 (6.6) | 865 (6.7) | 81 (5.8) | |
| Unknown | 51 (0.4) | 44 (0.3) | 9 (3.0) | |
| Primary cancer diagnosis, No. (%) | <.001 | |||
| Leukemia | 4830 (33.6) | 4422 (34.2) | 388 (27.7) | |
| Acute lymphoblastic | 4329 (30.1) | 3983 (30.7) | 346 (24.7) | |
| Acute myeloid | 356 (2.5) | 327 (2.5) | 29 (2.1) | |
| Other | 145 (1.0) | 132 (1.0) | 13 (0.9) | |
| CNS cancer | 1877 (13.1) | 1714 (13.3) | 163 (11.7) | |
| Astrocytoma | 1182 (8.2) | 1007 (8.5) | 85 (6.1) | |
| Medulloblastoma | 381 (2.7) | 334 (2.6) | 47 (3.4) | |
| Other CNS | 314 (2.2) | 283 (2.2) | 31 (2.2) | |
| Hodgkin lymphoma | 1927 (13.4) | 1474 (11.4) | 453 (32.3) | |
| Non-Hodgkin lymphoma | 1080 (7.5) | 998 (7.7) | 82 (5.8) | |
| Kidney tumors | 1256 (8.7) | 1205 (9.3) | 51 (3.6) | |
| Neuroblastoma | 955 (6.7) | 910 (7.0) | 45 (3.2) | |
| Bone and soft tissue tumors | 2434 (17.0) | 2214 (17.1) | 220 (15.7) | |
| Soft tissue sarcoma | 1246 (8.7) | 1134 (8.8) | 112 (8.0) | |
| Ewing sarcoma | 403 (2.8) | 354 (2.7) | 49 (3.5) | |
| Osteosarcoma | 733 (5.1) | 678 (5.2) | 55 (3.9) | |
| Other bone tumors | 52 (0.4) | 48 (0.4) | 4 (0.3) | |
| Childhood cancer therapy, No. (%) | <.001 | |||
| Surgery only | 909 (6.3) | 871 (6.7) | 38 (2.7) | |
| Radiation therapy only | 1514 (10.5) | 1238 (9.6) | 276 (19.7) | |
| Chemotherapy and radiation therapy | 7022 (48.9) | 6168 (47.6) | 854 (60.9) | |
| Chemotherapy and no radiation therapy | 3091 (21.5) | 2978 (23.0) | 113 (8.1) | |
| No treatment | 12 (0.1) | 11 (0.1) | 1 (0.1) | |
| Treatment unknown | 1811 (12.6) | 1691 (13.1) | 120 (8.6) | |
| Vital status, No. (%) | <.001 | |||
| Alive | 12 340 (85.9) | 11 285 (87.1) | 1055 (75.2) | |
| Deceased | 2019 (14.1) | 1672 (12.9) | 347 (24.8) | |
| Mean age at subsequent neoplasm diagnosis, y (SD) | N/A | N/A | 29.5 (9.1) | |
| Time in years from childhood cancer diagnosis to second neoplasm diagnosis (SD) | N/A | N/A | 19.0 (6.7) | |
| Mean years of follow-up (SD) | 22.7 (6.8) | 22.4 (6.8) | 25.5 (6.7) | <.001 |
*
All statistical tests were two-sided. We use t tests for comparison of data with continuous variables and χ2 tests for dichotomous data. CNS = central nervous system; SD = standard deviation.